Actavis renamed as Allergan
This article was originally published in Scrip
Actavis has now changed its name to Allergan and began trading under its new moniker on the New York Stock Exchange on 15 June. The name change follows the acquisition of Allergan in March 2015 and the approval of the name change by Actavis shareholders on 5 June; it announced its intention to change names in February. The company's US and Canadian generics business is to retain the Actavis name. CEO and president Brent Saunders said, "By adopting the Allergan name, we are ensuring that our corporate identity reflects the transformation of our company within the pharmaceutical industry and our position as a dynamic new breed of company – a leader in growth pharma." The combination of the two firms has created a new top-10 pharma company by revenues.
You may also be interested in...
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.
Allergan PLC will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva Pharmaceutical Industries Ltd. to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its dealmaking net.
Vigorous regulatory scrutiny is a given, but opinions vary about how much the companies’ respective PBM businesses present a major antitrust risk.